Appendix 4c – q3 fy25 quarterly cash flow report

Highlights reported positive topline data for ath434-201 randomized, double-blind phase 2 clinical trial in multiple system atrophy (msa) led by robust clinical efficacy phase 2 data featured in an oral presentation at the american academy of neurology annual meeting ath434-202 open-label trial in advanced msa completed in march 2025 cash balance on 31 march 2025 of a$17.96m with an additional a$27.1m raised subsequent to the end of the quarter melbourne, australia and san francisco, april 30, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its appendix 4c quarterly cash flow report and update on company activities for the quarter ending 31 march 2025 (q3 fy25). david stamler, m.d.
MSA Ratings Summary
MSA Quant Ranking